Pyrotinib and Trastuzumab Plus Chemotherapy Serve as an Acceptable Neoadjuvant Regimen Exhibiting Good Efficacy and Tolerance in HER2-Positive Breast Cancer Patients

医学 内科学 乳腺癌 曲妥珠单抗 肿瘤科 卡铂 多西紫杉醇 胃肠病学 化疗 癌症 顺铂
作者
Yibo Chen,Tianyi Zhang,Rui Zhang,X B Cao
出处
期刊:Cancer Biotherapy and Radiopharmaceuticals [Mary Ann Liebert, Inc.]
卷期号:39 (6): 435-440
标识
DOI:10.1089/cbr.2023.0175
摘要

Objective: Pyrotinib, a new irreversible dual pan-human epidermal growth factor receptor 2 (HER2) receptor tyrosine kinase inhibitor blocking EGFR and HER2, has achieved a promising efficacy for advanced HER2-positive (HER2+) breast cancer. This study intended to further investigate the efficacy and safety of neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2+ breast cancer treatment. Methods: Thirty-eight HER2+ breast cancer patients who received neoadjuvant pyrotinib and trastuzumab plus chemotherapy (docetaxel and carboplatin) were retrospectively reviewed. Clinical response by Response Evaluation Criteria in Solid Tumors (RECIST), pathological complete response (pCR), and adverse events data was retrieved. Results: According to the RECIST, the complete response rate was 0.0%, 10.5%, and 15.8% after second-cycle, fourth-cycle, and sixth-cycle therapy, respectively; whereas the objective response rate was 76.3%, 92.1%, and 100.0%, accordingly. The total pCR (tpCR) rate was 52.6%, the pCR rate of the breast was also 52.6%, and the pCR rate of lymph nodes was 86.8%. The tpCR rate was lower in patients with HER2 immunohistochemistry (IHC)++ and amplification by fluorescent in situ hybridization (FISH) than in those with HER2 IHC+++ (14.3% vs. 61.3%, p = 0.024), which was also lower in patients with Ki-67 expression ≥30% than in those with Ki-67 expression <30% (40.0% vs. 76.9%, p = 0.031). The common adverse events included diarrhea (84.2%), anemia (73.7%), nausea and vomiting (63.2%), fatigue (50.0%), hypomagnesemia (44.7%), leukopenia (42.1%), thrombocytopenia (39.5%), elevated transaminase (36.8%), and pruritus (31.6%). Conclusions: Pyrotinib and trastuzumab plus chemotherapy serve as an acceptable neoadjuvant regimen exhibiting good efficacy and tolerance in HER2+ breast cancer patients, while further large-scale validation is warranted.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
田田发布了新的文献求助10
1秒前
李子敬完成签到,获得积分10
1秒前
等等发布了新的文献求助10
1秒前
小蘑菇应助典雅迎海采纳,获得10
1秒前
lizzy完成签到 ,获得积分10
1秒前
Lazarus完成签到,获得积分10
2秒前
2秒前
111完成签到,获得积分10
3秒前
方明会完成签到,获得积分20
4秒前
4秒前
YUNG完成签到 ,获得积分10
4秒前
玩命的易绿应助小琰砸采纳,获得10
4秒前
奇奇完成签到,获得积分20
4秒前
谦谦神棍发布了新的文献求助10
4秒前
厚切柠檬发布了新的文献求助30
5秒前
二仙桥成华大道完成签到,获得积分10
5秒前
6秒前
lius完成签到,获得积分10
6秒前
CiCi发布了新的文献求助10
6秒前
hongjie_w发布了新的文献求助10
7秒前
今后应助hufan2441采纳,获得10
8秒前
8秒前
李健应助wjx采纳,获得10
8秒前
梁三柏应助忧虑的问寒采纳,获得10
9秒前
10秒前
11秒前
粉红大叔完成签到 ,获得积分10
11秒前
11秒前
无语的沉鱼完成签到,获得积分10
12秒前
12秒前
123完成签到,获得积分10
12秒前
12秒前
量子星尘发布了新的文献求助10
14秒前
音吹完成签到,获得积分20
14秒前
YJJ完成签到,获得积分20
14秒前
小余发布了新的文献求助20
15秒前
15秒前
独立卫生间完成签到,获得积分10
15秒前
CodeCraft应助applooc采纳,获得10
16秒前
hufan2441完成签到,获得积分10
16秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Effective Learning and Mental Wellbeing 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3974856
求助须知:如何正确求助?哪些是违规求助? 3519400
关于积分的说明 11198085
捐赠科研通 3255563
什么是DOI,文献DOI怎么找? 1797860
邀请新用户注册赠送积分活动 877208
科研通“疑难数据库(出版商)”最低求助积分说明 806219